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AbstrACt
Introduction The introduction of intra- arterial 
thrombectomy (IAT) challenges acute stroke care 
organisations to provide fast access to acute stroke 
therapies. Parameters of pathway performance include 
distances to primary and comprehensive stroke centres 
(CSCs), time to treatment and availability of ambulance 
services. Further expansion of IAT centres may increase 
treatment rates yet could affect efficient use of resources 
and quality of care due to lower treatment volume. The 
aim was to study the organisation of care and patient 
logistics of IAT for patients with ischaemic stroke in the 
Netherlands.
Methods and analyses Using a simulation modelling 
approach, we will quantify performance of 16 primary 
and CSCs offering IAT in the Netherlands. Patient data 
concerning both prehospital and intrahospital pathway 
logistics will be collected and used as input for model 
validation. A previously validated simulation model for 
intravenous thrombolysis (IVT) patients will be expanded 
with data of the MR CLEAN (Multicenter Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic 
Stroke in the Netherlands) Registry and trials performed 
in the Collaboration for New Treatments in Acute Stroke 
consortium to represent patient logistics, time delays and 
outcomes in IAT patients. Simulation experiments aim to 
assess effectiveness and efficiency of alternative network 
topologies, that is, IAT with or without IVT at the nearest 
primary stroke centre (PSC) versus centralised care at 
a CSC. Primary outcomes are IAT treatment rates and 
clinical outcome according to the modified Rankin Scale. 
Secondary outcomes include onset- to- treatment time and 
resource use. Mann- Whitney U and Fisher’s exact tests 
will be used to estimate differences for continuous and 
categorical variables. Model and parameter uncertainty 
will be tested using sensitivity analyses.
Ethics and dissemination This will be the first study 
to examine the organisation of acute stroke care for 
IAT delivery on a national scale using discrete event 
simulation. There are no ethics or safety concerns 
regarding the dissemination of information, which includes 
publication in peer- reviewed journals and (inter)national 
conference presentations.
trial registration number ISRCTN99503308, 
ISRCTN76741621, ISRCTN19922220, ISRCTN80619088, 
NCT03608423; Pre- results.
IntroduCtIon
For patients with acute ischaemic stroke, 
reperfusion therapies comprise intrave-
nous thrombolysis (IVT) administered up 
to 4.5 hours after onset and intra- arterial 
thrombectomy (IAT) administered up to 
6 hours and in selected patients even up to 
24 hours.1–7 Functional recovery following 
treatment is strongly determined by the time 
interval between symptom onset and reper-
fusion. For every 9 min delay along the care 
pathway, 1 in every 100 patients treated with 
IAT has a worse disability outcome (higher 
modified Rankin Scale (mRS) score by one 
or more levels).8 As such, timely arrival at the 
hospital and minimising the overall onset- 
to- treatment time are of critical importance. 
Following symptom onset, patients are typi-
cally transported to the nearest hospital 
capable of administering IVT, which can be 
either a PSC or a CSC. In parallel with admin-
istering the bolus for IVT, additional neuro-
imaging is performed in order to detect 
large- vessel occlusion (LVO). In case of an 
strengths and limitations of this study
 ► The proposed simulation modelling study collects 
patient- level data from all intervention centres in the 
Netherlands that provide intra- arterial thrombecto-
my for patients with acute ischaemic stroke.
 ► Information from prehospital stroke services, includ-
ing emergency medical services, is included in the 
model.
 ► Information on costs associated with pathway set- 
up and innovations foreseen in acute stroke treat-
ment are included.
 ► Model results are estimations which have to be test-
ed in clinical practice.
 ► Input parameters for model building contain estima-
tions of time delays and diagnostic procedures that 
may have changed over time.
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LVO, patients may become eligible for IAT after which 
transfer to a CSC is arranged, if patients are initially 
admitted to a PSC.
The transfer of patients to a CSC following IVT diag-
nostic work- up and/or treatment at a PSC is called the 
drip- and- ship (DS) approach. In addition to the DS 
approach, patients may be transported directly to the 
CSC bypassing the PSC, which is called the mothership 
(MS) approach. Currently there are no formal policies 
supporting the latter, as it necessitates accurate prehos-
pital triage objectifying LVO with sufficient accuracy. 
Timely patient arrival and treatment with reperfusion 
therapies depends on a number of factors such as the 
geographical distribution and distances between PSCs 
and CSCs in relation to the location of the patient. 
Arrangements made by local emergency medical services 
concerning referral patterns of suspected stroke victims 
and the quality and set- up of road networks also play a 
role, as does potential traffic congestion.
In the Netherlands, 16 medical centres that partici-
pated in the MR CLEAN trial are currently reimbursed 
for IAT. However, these hospitals are unevenly distributed, 
leaving certain regions potentially underserved, while in 
some areas there is a surplus of IAT centres. Insight into 
factors determining the potential optimal and most effi-
cient way to organise acute stroke care is currently lacking 
but urgently needed to support clinicians and decision- 
makers. A key question is what would be the optimal 
distribution of CSCs within a region, taking into account 
the effects of additional travel distances, available clin-
ical expertise, treatment volumes and capacity of hospi-
tals? Are there regions underserved or overserved with 
CSCs and what would be the potential consequences of 
adding/removing CSCs within specific regions?
In this study, we aimed to quantify pathway logis-
tics, that is, stroke onset and time delays associated 
with prehospital and intrahospital care services among 
patients treated with IAT with or without IVT. From this 
baseline assessment, a simulation model will be built that 
describes all activities and treatments performed along 
the acute stroke pathway. A generic model will be devel-
oped based on the set- up of IAT delivery in the region 
of Northern Netherlands and extended using results of 
the MR CLEAN registry9 and data of five randomised 
clinical trials (RCTs) performed in the Collaboration for 
New Treatments in Acute Stroke (CONTRAST) consor-
tium ( www. contrast- consortium. nl). The MR CLEAN 
registry is an ongoing, prospective, observational study in 
all centres that perform IAT in the Netherlands. Within 
CONTRAST, five large clinical trials will be performed 
to test novel treatment strategies for stroke. This will be 
complemented by a preclinical programme, develop-
ment of a large biobank, and identification of challenges 
and solutions for organisational models. Retrospective 
data from the MR CLEAN registry, combined with data 
from emergency medical services, will serve as input 
for the development of a baseline simulation model for 
regional IAT delivery. Next, prospective data capturing 
using results from ongoing trials performed within 
CONTRAST will be used to further develop the model. 
Simulation experiments will be performed to assess effec-
tiveness and efficiency of alternative network topologies, 
that is, primary and comprehensive stroke services (DS 
approach) versus a service delivery based on compre-
hensive and centralised care (MS approach). Model 
parameters will be extended by assigning unit costs to 
activities allowing for economic analyses. The latter will 
involve collection of detailed information on resource 
use allowing for microcosting studies and subsequent use 
in cost- benefit and/or cost- effectiveness analyses.
Aims and hypotheses
Primary aim: to develop a simulation model for IAT in the 
Netherlands and to extend the model to reflect regional 
differences.
Secondary aims: to estimate the effectiveness of alterna-
tive network topologies on IVT and/or IAT treatment 
rates, geographical access to CSCs, time to treatment, 
treatment volumes and patient disability as measured by 
the mRS. Also, potential areas for pathway improvements 
in regional stroke care systems will be identified.
Tertiary aims: to extend the model with costs estimations 
of procedures and activities performed along the acute 
stroke pathway, allowing for elaborate economic evalua-
tion. Also, the assessment and potential implementation 




This study uses discrete event simulation modelling in 
which care pathways can be represented ‘in silico’ by 
quantifying pathway performance.10–12 In case of acute 
stroke treatment, information on time delays sustained 
by patients and diagnostic steps performed up to treat-
ment with IVT and IAT are collected. In addition, patient 
demographics (age), exclusion and inclusion criteria, 
and follow- up data up to 3 months poststroke will be 
included. Previous research has demonstrated that simu-
lation models for representing the acute stroke pathway 
can be accurately developed in different settings.13–17 
Typically, simulation modelling involves a number of 
consecutive steps, including model building, validation 
and experimentation. Model building starts with the 
conceptual representation of care pathways in building 
block, such as incidents, time delays, queues, resources 
and ultimately outcome. Next, the model needs to be 
populated through collection of empirical data reflecting 
actual pathway performance, for which a combination 
of real- world datasets is used. For hospital items, we will 
rely on case report forms (CRFs) collected in the RCTs 
in the CONTRAST consortium involving 16 hospitals in 
the Netherlands that provide IAT. In addition, collabo-
ration with regional ambulance services will be set up in 
order to collect prehospital items, such as time of 911 call, 
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Figure 1 Description of the drip- and- ship model. CTA, CT angiography; CTP, CT perfusion; GP, general practitioner; IAT, intra- 
arterial thrombectomy; IVT, intravenous thrombolysis; MRA, magnetic resonance angiography; N, no; Y, yes.
time spent on scene, transportation time to the hospital 
and general referral patterns. Real- world data collected 
in each step of the pathway will be analysed to distin-
guish statistical distributions using the statistical software 
package ExpertFit.18 Based on the statistical distributions 
identified, hypothetical patients passing through the 
model will be assigned a certain time delay, and diag-
nostic accuracy for each step along the pathway. Model 
outcomes include the proportion of patients treated with 
IAT, time to treatment and functional outcome after 90 
days. These results will then be validated comparing them 
to observed time delays and outcomes observed in clinical 
practice. Following model validation, experiments will be 
performed in which scenarios of alternative set- ups of the 
organisational models will be evaluated. Descriptions of 
the acute stroke pathway in both the DS and MS organisa-
tional models in Northern Netherlands are presented in 
figures 1 and 2.
study population
For this study, we will use data from patients with acute 
stroke who underwent IAT with or without IVT. A baseline 
model will be developed using a subset of patient infor-
mation collected in the ongoing cohort study MR CLEAN 
Registry. Following the initial model patients treated 
in other regions in the Netherlands will be included. 
In later stages of model development, alternative treat-
ment modalities may become apparent, such as treating 
patients with IAT up to 24 hours or including patients who 
underwent prehospital treatment in a mobile stroke unit. 
The acute stroke phase is defined as the time window in 
which acute reperfusion therapies are being used. This 
can be the case up to a maximum of 24 hours following 
symptom onset. In these cases, the parameters under-
lying the model will be changed accordingly. Modelling 
the hypothetical introduction of a mobile stroke unit 
will involve changing prehospital stroke management. In 
such a scenario, an expedited and optimised process of 
initial diagnostic assessment and triage is assumed.
Public and patient involvement
Patients and the public were involved in the conception of 
the topics to be addressed in the CONTRAST consortium. 
Study results will be disseminated through newsletters, 
poster presentations, and publications in newspapers, lay 
journals and publication in peer- reviewed journals.
data to be collected
An overview of all data items collected for the simulation 
model is presented in a table as supplementary mate-
rial (online supplementary table S1, Overview of data 
collection). Based on these data, time intervals reflecting 
pathway efficiencies will be calculated, such as the time 
from symptom onset to CT/CT angiography (CTA) and 
door- to- CT/CTA times for patients arriving at a PSC and 
after secondary transfer to the CSC, if necessary.
Hospital data
Within CONTRAST, five RCTs are performed that 
serve as input for the proposed simulation modelling 
studies: MR ASAP (NL60258.078.17), MR CLEAN LATE 
(NL58246.078.17), MR CLEAN MED (ISCRTN76741621), 
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Figure 2 Description of the mothership model. CTA, CT angiography; CTP, CT perfusion; GP, general practitioner; IAT, intra- 
arterial thrombectomy; IVT, intravenous thrombolysis; MRA, magnetic resonance angiography; N, no; Y, yes.
MR CLEAN NO IV (ISRCTN80619088). Each interven-
tion centre uses a standardised, customised and web- based 
electronic CRF to document all steps in the care process. 
All data will be entered locally in a web- based database 
(OpenClinica). A copy of the CRF documents used in the 
clinical trials can be found online ( www. contrast- consor-
tium. nl). All studies aimed to collect a large set of items 
containing, among others, a description of the workflow, 
including time of symptom onset or last seen well, time 
of arrival of the first hospital and whether the patient was 
transferred from another hospital. Within the hospital, 
time to CT scan and advanced imaging (CTA/magnetic 
resonance angiography/digital subtraction angiography/
perfusion imaging) are collected according to local 
procedures. Also, start of IVT (bolus infusion), patient 
arrival in the angiosuite, groin puncture, device attempts, 
recanalisation and sheath withdrawal/end of procedure 
are collected. In addition, anaesthetic team presence and 
management procedures are recorded.
Prehospital data
For the collection of prehospital data collaboration with 
regional ambulance services is being set up. Items will 
include time delays, diagnostics and geographical infor-
mation on referral patterns. Time delays include the time 
of 911 call, arrival at the location of the patient, departure 
at the location of the patient and arrival at the hospital. 
Diagnostic items include mode of referral (general 
practitioner, 911 or other), initial working diagnosis 
set by 911 dispatch and ambulance personnel, and the 
level of urgent transportation (ie, blue lights or other). 
Geographical information includes the postal codes of 
the location of the patient, departure location of the 
ambulance vehicle, and location of the PSC and/or CSC.
Baseline data
Prior to the CONTRAST study, all hospitals contributed 
to the MR CLEAN Registry, an online and ongoing data-
base to monitor implementation and safety of IAT in the 
Netherlands.9 For CONTRAST, the variables are similar 
to those collected in the MR CLEAN Registry. In addition, 
prehospital information available at regional ambulance 
services will be collected.
The baseline discrete event simulation model will be 
developed using data from 296 patients who underwent 
IAT at the University Medical Centre Groningen between 
July 2014 and November 2017. For these patients, intra-
hospital time delays and diagnostic steps were already 
collected as part of the ongoing MR CLEAN Registry 
and were subsequently used for model development and 
validation. In addition, prehospital items as described 
previously were collected in collaboration with regional 
ambulance services.
outcome measures
Outcomes will be estimated by the simulation model 
using parameter distributions as observed in clinical prac-
tice using real- world data.
Primary outcomes include IAT treatment rates and clin-
ical outcome according to the mRS.
Secondary outcomes include process times, such as 
symptom onset to hospital arrival, door to needle and 
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groin puncture, arrival angiosuite, recanalisation, onset- 
to- treatment time of IVT and/or IAT, and interhospital 
transportation times for those patients who were trans-
ferred to a CSC after initial diagnosis and/or treatment 
with IVT at a PSC. In addition, the time interval of referral 
from the PSC to CSC is included.
Tertiary outcomes include treatment volume, direct costs, 
indirect costs and societal costs. This will include fixed 
and variable costs of providing services related to IAT 
delivery.
Ethics and dissemination
Both the MR CLEAN and CONTRAST databases include 
patients for which informed consent had been obtained, 
which was extended for use in our simulation model-
ling study. All data used for model building have been 
completely anonymised, performed by local researchers 
under auspices of the principal investigators for the MR 
CLEAN Registry and CONTRAST studies. Accordingly, 
no additional approval from our local ethics committee 
is required, as this represents a simulation study using an 
anonymised dataset.
In order to link data collected of patients treated 
with IAT after study enrolment in the hospital to corre-
sponding data collected by ambulance services, iden-
tifiable information from patients will be used under a 
strict protocol compliant with the Dutch Personal Data 
Protection Act. This protocol for using prehospital ambu-
lance data meets the criteria for a waiver of consent from 
the University Medical Centre Groningen Institutional 
Review Board, for which formal approval was already 
obtained. Following successful linking of prehospital and 
inhospital data, note, however, that also these data were 
anonymised. Prior to the exchange of information, a data 
transfer and processing agreement was agreed on and 
signed by each provider of regional ambulance services.
Study results will be published in peer- reviewed journals 
and (inter)national conference presentations. Centres 
that have participated in the study will have access to their 
own data and results.
study sites
Sixteen hospitals providing IAT will participate. In addi-
tion, regional ambulance services in the catchment area 
of intervention centres will be asked to participate. The 
overview of intervention centres, their catchment area 
and regional ambulance services active in the region are 
provided as supplementary material (online supplemen-
tary figure S1, Overview of IAT centres and ambulance 
services).
statistical analyses
Descriptive statistics will be used to characterise the popu-
lation and regional differences. Mann- Whitney U and 
Fisher’s exact tests are used to estimate the differences for 
continuous and categorical variables. Model and param-
eter uncertainty will be tested using sensitivity analyses.
Approach to missing data
Multiple imputation techniques will be used to handle 
missing data. The impact of missing data will be analysed 
by performing sensitivity analyses. Once missing data or 
errors are identified, all corrections made will be docu-
mented. All data will be documented and displayed in an 
appropriate flow diagram.
Model validation
Internal validation will be performed by comparing 
model performance with observed performance of the 
stroke system to ascertain whether the model represented 
the real system accurately. External validation of the 
baseline model will be performed by using the pathway 
performance of other PSCs and CSCs participating in 
the CONTRAST consortium. As such, the model devel-
oped for one region will be extended to other parts of 
the Netherlands by changing the distributions under-
lying the simulation model. This means that the model is 
repopulated by real- world data originating from different 
regions, including both intrahospital and prehospital 
data. As we will adopt one uniform method for data 
collected in both the prehospital and intrahospital path-
ways, similar procedures for model building, validation 
and experimentation can be followed.
study organisation
The CONTRAST consortium is a nationwide collabo-
ration of clinical and translational scientists from all 
academic and large clinical centres who want to act 
together to improve the treatment of acute stroke in 
the Netherlands. Five large acute stroke trials to test 
novel treatment strategies will be performed, including 
prehospital augmentation of collateral blood flow and 
blood pressure management (MR ASAP), antithrom-
botics to prevent microvascular occlusion after IAT (MR 
CLEAN MED), immediate IAT without preceding throm-
bolysis (MR CLEAN NO IV), IAT in the time window of 
6–24 hours (MR CLEAN LATE) and minimally invasive 
endoscopy- guided surgery for intracerebral haemorrhage 
(Dutch ICH trial). Discrete event simulation modelling 
is applied with data from these trials to optimise acute 
stroke care delivery.
dIsCussIon
This simulation modelling study will evaluate the set- up 
of acute stroke services for patients undergoing IAT in 
a specific geographical setting, that is, the Netherlands. 
However, the model foreseen may also serve as a plan-
ning and evaluation tool for other regions and countries. 
Already from an early phase onwards, the potential conse-
quences of the clinical trials performed in CONTRAST 
on the organisation of acute stroke care will be assessed. 
Benefits of innovations foreseen in prehospital as well as 
hospital- based diagnosis and treatment will be estimated 
on a regional and national scale. Likewise, the optimal 
organisation ensuing from these reorganising care 
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processes may be identified and taken into account, given 
the available resources and capacity. Another important 
aspect that will be studied is how redistribution of PSCs 
and CSCs within certain regions will affect time to treat-
ment for both IVT and IAT.19 Experiments from simu-
lation models will help to elucidate factors determining 
optimal stroke pathway set- up and to identify potential 
targets for further optimisation of pathway performance. 
Simulation modelling also allows for making exact esti-
mations on effects on patients health and costs when 
adding or removing IAT centres in specific regions, 
thereby supporting clinicians and policy makers in 
decision- making.15
Our simulation modelling approach has several 
strengths. First, the prospective design and uniform 
methods for data collection both in the prehospital and 
intrahospital phases will ensure a high quality of data 
capture. The use of real- world data will support the 
external validation of results obtained and is a unique 
feature of the proposed modelling study. Also, in terms 
of efficiency, simulation modelling is an attractive option 
as it uses already collected information in clinical trials 
and by ambulance services. Second, the model will have a 
comprehensive scope, contrary to current improvement 
approaches characterised by monodimensional interven-
tions.20–22 Implementation problems such as how many 
CSCs would a region need or where they should ideally 
be located require a multifaceted solution, and could 
therefore benefit from a modelling approach. Data used 
for model input will be collected in various regions of the 
Netherlands reflecting differences in access to PSCs and 
CSCs, road networks and potential traffic congestion. 
Third, the model builds on a previously developed simula-
tion model for IVT treatment in Northern Netherlands.10 
As such, we have demonstrated that model building and 
validation are feasible. Finally, the model can be extended 
to include unit costs for elaborate economic analyses. The 
comprehensive character of the modelling approach also 
allows considering potential interaction effects between 
variables and has a quadruple dimensional approach in 
terms of measuring outcomes, as it can capture effects on 
clinical outcomes, time to treatment, referral patterns and 
costs of processes associated with IVT and IAT delivery.
Serving as a precursor for clinical validation, results 
obtained from modelling studies should always be inter-
preted with care as these results do not represent actual 
patients. However, from an economics and business 
approach, each treatment can be represented as the sum 
of time delays and diagnostics performed along the care 
pathway, and as such can be quantified and in turn repre-
sented in silico by computer models. One of the main 
questions is whether there is benefit in bypassing the 
nearest PSC to transport the patient directly to a CSC. 
At the moment, there is no consensus which prehospital 
scale to use in order to quantify stroke severity, and no 
agreed on triage instrument exists to guide transfer of 
patients to specific hospitals. Typically, in case of a positive 
trial result in CONTRAST, this will have a direct impact 
on the organisational model for IAT delivery, either 
by suggesting to bypass PSCs (MR CLEAN NO IV) by 
extending the time window for reperfusion therapies (MR 
CLEAN LATE) or to change prehospital stroke manage-
ment (MR ASAP). As a consequence, alternative set- up 
of services is foreseen, in which accurate estimations on 
effectiveness, time to treatment and cost- effectiveness are 
required to support decision- making.
In summary, the proposed modelling study will inves-
tigate current organisational models for IAT delivery in 
the Netherlands. Based on input from real- world clinical 
studies performed in the CONTRAST consortium insight 
into current treatment delays and workflow performance 
of IAT centres will be obtained. Next, simulation model-
ling studies will support design of optimal distribution of 
IAT centres, in order to improve patient outcomes and 
increase the proportion of patients eligible for IAT.
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